Angiotensin converting enzyme inhibition worsens the excretory phase of diuretic renography for obstructive hydronephrosis.
OBJECTIVE
A growing body of evidence identifies the renin-angiotensin system as a key factor in the onset and progression of renal damage in chronic partial obstruction, which often represents a complex diagnostic challenge. A prospective study was undertaken to evaluate the role of captopril mercaptoacetyltriglycine-3 (MAG-3) renography as an early diagnostic test of obstruction. We report the results in a subgroup of children who underwent surgical correction for pyeloureteral obstruction.


METHODS
Pyeloplasty was performed in 12 patients, including 10 males, 2 to 72 months old (median age 7) with unilateral hydronephrosis, including normal renal function and blood pressure. Basal and captopril enhanced diuretic renography with 99mtechnetium MAG-3 was performed within 24 hours using the same hydration and diuretic stimulus (0.75 mg./kg. furosemide), and 0.75 mg./kg. captopril was administered orally 60 to 90 minutes before scintigraphy.


RESULTS
No adverse effects or modifications of the blood pressure were observed after captopril administration. The diuretic response was deeply worsened by angiotensin converting enzyme inhibition in each hydronephrotic kidney even when the basal study was only slightly abnormal (15-minute washout basal -27 +/- 16%, after captopril -9 +/- 13, p <0.005). After surgical correction the diuretic washout during angiotensin inhibition appeared normal in all patients (15-minute washout -56 +/- 14%). Separate renal function and parenchymal transit of MAG-3 were not modified by angiotensin converting enzyme inhibition, preoperatively or postoperatively.


CONCLUSIONS
Our data confirm the influence of angiotensin on the kidney excretory system in human hydronephrosis and suggest a role for captopril enhanced diuretic renography in the early diagnosis of pyeloureteral obstruction. Further work is needed to evaluate angiotensin converting enzyme inhibition as a protective agent in obstructive nephropathy.
Zucchetta
P
P
Nuclear Medicine Service 1 and the Pediatrics Department, Institute of Urology, Padua, Italy.
Carasi
C
C
Marzola
M C
MC
Murer
L
L
Passerini-Glazel
G
G
Rigamonti
W
W
Zacchello
G
G
Bui
F
F
Montini
G
G
D000806:Angiotensin-Converting Enzyme Inhibitors; D002216:Captopril; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D006869:Hydronephrosis / Q000000981:diagnostic imaging* / Q000503:physiopathology*; D007223:Infant; D008297:Male; D011446:Prospective Studies; D011866:Radioisotope Renography; D019275:Radiopharmaceuticals; D012084:Renin-Angiotensin System / Q000502:physiology; D017263:Technetium Tc 99m Mertiatide
D000806:Angiotensin-Converting Enzyme Inhibitors; D019275:Radiopharmaceuticals; D017263:Technetium Tc 99m Mertiatide; D002216:Captopril